AIM ImmunoTech announced it has regained compliance with the NYSE American's continued listing standards after resolving a stockholder equity deficiency. The company was formally notified by the exchange on June 12, 2026, that it had successfully addressed all previously identified issues.
Key Details
- Compliance Regained: The company is now in compliance with NYSE American Company Guide Sections 1003(a)(i), (ii), and (iii), specifically resolving the stockholders' equity requirement.
- Capital Raised: Compliance was achieved after raising approximately $8.5 million in gross proceeds through a series of warrant exercises and stock sales in May and June 2026, bringing stockholders' equity above the $6.0 million minimum.
- Ticker Update: As a result, the "below compliance" (.BC) indicator will be removed from the company's trading symbol, and it will be taken off the NYSE American's list of noncompliant issuers.